Meningitis C vaccine

From WikiProjectMed
Jump to navigation Jump to search
Meningoccal C vaccine
Menitorix vial.jpg
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽

Meningoccal C vaccine (MenC), is a meningitis vaccine that protects against Neisseria meningitidis type C.[1][2] It is available either combined with Haemophilus type b vaccine or with other types of meningitis, the MenACWY vaccine.[3] It has been shown to dramatically reduce cases of meningitis C to levels of almost none, when part of a routine vaccination schedule.[3]

Common side effects include redness, pain and swelling at the site of injection.[3] There may be a slight fever, feeling of not wanting to eat, a tummy upset, irritability and poor sleep.[3] [3] Rarely, there may be dizziness, high fever or fainting.

The first monovalent MenC was licensed in the UK in 1999 and entered routine vaccination schedules there form November of that year.[1] By 2001, MenC cases in the UK dropped 87% in those who received the vaccine.[1] It continued to be used as a monovalent vaccine until 2016.[3]


  1. 1.0 1.1 1.2 Pollard, Andrew J.; Snape, Matthew D.; Sadarangani, Manish (2021). "22. Meningoccal vaccines". In Vesikari, Timo; Damme, Pierre Van (eds.). Pediatric Vaccines and Vaccinations: A European Textbook (Second ed.). Switzerland: Springer. pp. 253–254. ISBN 978-3-030-77172-0. Archived from the original on 2022-06-14. Retrieved 2022-06-13.
  2. Suryadevara, Manika (2021). "19. Meningococcus". In Domachowske, Joseph; Suryadevara, Manika (eds.). Vaccines: A Clinical Overview and Practical Guide. Switzerland: Springer. pp. 235–246. ISBN 978-3-030-58416-0. Archived from the original on 2022-01-11. Retrieved 2022-06-13.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 "MenC Vaccine (Meningococcal C Vaccine)". Vaccine Knowledge Projective. 15 March 2022. Archived from the original on 16 November 2021. Retrieved 13 June 2022.